Saladax Develops First-Ever Rapid Test for an Antipsychotic Drug Using a Single Drop of Blood to Aid Psychiatrists in the Treatment of Schizophrenia
5.9.2019 16:30:00 EEST | Business Wire | Press release
Saladax Biomedical today announced that its MyCare Insite Clozapine Test is now CE marked for use on the MyCare Insite. The MyCare Insite Clozapine Test is the first and only rapid point-of-care test CE marked to aid mental health professionals in the treatment and monitoring of patients with schizophrenia.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190905005085/en/
The MyCare Insite Clozapine Test delivers accurate and precise clozapine blood levels comparable to laboratory results. Psychiatrists need immediate information to make informed decisions during a patient visit. The MyCare Insite Clozapine Test addresses this unmet medical need by providing answers in only six minutes. Clinicians, in consultation with their patients, can use these results to make real-time adjustments to better manage their patients.
"Mental health professionals have very few tools to aid in patient treatment; as a result, patients are suffering. The MyCare Insite Clozapine Test provides clinicians a first of its kind device. The test is evidence of how Saladax is once again setting new standards for innovation in the treatment and monitoring of patients," said Dr. Salvatore Salamone, CEO and Founder of Saladax Biomedical. "We are changing psychiatry with a single drop of blood.”
ABOUT PSYCHOSIS
Psychosis is a condition that affects the way your brain processes information. It causes you to lose touch with reality. Psychotic disorders, like schizophrenia, involve psychosis that usually affects you for the first time in the late teen years or early adulthood. Young people are especially at risk, but doctors don’t know why.
ABOUT THE MyCARE INSITE CLOZAPINE TEST
The MyCare Insite Clozapine Test is intended for the in vitro quantitative measurement of clozapine in human capillary finger blood using the MyCare Insite.
ABOUT SALADAX
Founded in 2004, Saladax Biomedical, Inc. is a privately held company headquartered as an anchor tenant at Ben Franklin TechVentures® located on Lehigh University’s campus in Bethlehem, PA.
Saladax develops rapid blood tests for point-of-care and for laboratory analysers for use in psychiatry and oncology. The Saladax MyCare Psychiatry line provides drug levels for greater insight into patient adherence and possible causes of treatment failures. These tests enable psychiatrists to more accurately assess adherence and better adjust medication dosing. Saladax believes that truly personalized medicine can only exist when the right drug is taken at the right dose. Our diagnostic reagent kits are distributed worldwide and are pending approval in the United States. Saladax is ISO 13485:2016 certified.
For more information, visit Saladax.com or MyCareTests.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190905005085/en/
Contact information
Saladax Biomedical, Inc.
Salvatore Salamone, Ph.D., 610-419-6731
ssalamone@saladax.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sihoo esittelee uuden sukupolven ergonomisia toimistoratkaisuja ORGATEC 2026 -messuilla20.10.2026 21:14:00 EEST | Tiedote
ORGATEC 2026 -messujen lähestyessä ergonomisten istuinratkaisujen asiantuntija Sihoo esittelee uuden sukupolven työympäristöratkaisujaan hallissa 8.1, osastoilla A-060 ja B-061. Messujen teeman ”Tiloista vuorovaikutukseen: tilojen suunnittelu jatkuvasti muuttuvassa maailmassa” mukaisesti Sihoo esittelee, kuinka mukautuva ergonominen suunnittelu tukee asentojen vaihtelua ja nykyaikaisten työympäristöjen muuttuvia tarpeita. Tämä lehdistötiedote sisältää multimediaa. Katso koko julkaisu täällä: https://www.businesswire.com/news/home/20261020772047/fi/ Sihoo ORGATEC 2026 -messuilla Kölnissä Käyttötilanteisiin perustuva elämyksellinen tila Avoimeen tilakonseptiin perustuvalla Sihoon osastolla yhdistyvät oranssin ja valkoisen värimaailma, kerrokselliset kattorakenteet, läpikuultavat väliseinät ja integroitu valaistus. Korkeussäädettävillä työpöydillä ja näytöillä varustetut työpisteet sekä yhteistyöhön suunnitellut istuma-alueet jäljittelevät tuttuja toimistoympäristöjä ja havainnollistavat,
FPT and the Niels Bohr Institute Advance Vietnam–Denmark Collaboration in Quantum Talent Development20.10.2026 21:07:00 EEST | Press release
In the presence of H.E. Tô Lâm, General Secretary of the Communist Party of Vietnam and President of Vietnam, and His Majesty King Frederik X of Denmark, FPT Corporation, Vietnam's leading technology corporation operating in 31 countries and territories, and the Niels Bohr Institute (NBI), University of Copenhagen, one of the world's leading quantum research institutions, exchanged a Memorandum of Understanding (MoU) to strengthen collaboration in quantum science and technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261019899787/en/ General Secretary of the Communist Party of Vietnam Central Committee and President To Lam, Danish King Frederik X and delegates at the Vietnam–Denmark Business Forum in Copenhagen on October 20. (Photo: VNA) The partnership aims to strengthen scientific cooperation between Vietnam and Denmark by connecting Vietnamese researchers with one of the world's foremost centers for quantum resea
Grafana Labs Brings Faster Full-text Search and Smarter Data Optimization to Grafana Cloud at ObservabilityCON 202620.10.2026 20:00:00 EEST | Press release
Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that help teams manage their telemetry in the AI era, finding the right log line in seconds and keeping only the telemetry worth paying for as AI workloads scale. Major query performance enhancements to Grafana Cloud Logs, built on technology from the company's Logline acquisition, are now generally available, and Adaptive Logs Archive is in public preview. AI is massively increasing telemetry volumes. Coding agents are turning everyone into a developer, so more software is being built, faster, and all of it needs to be watched. The agents add to the load too, since every agent call and tool call emits its own telemetry. Left alone, observability costs grow with every new workload, which makes cost and query optimization non-negotiable for running AI at scale. In the 2026 State of Observability Report, also released this week by Grafana Labs and ETR, a Futurum co
Grafana Labs Charts the Path to Agentic Operations with Watchers, Pages, and Agent Observability at ObservabilityCON 202620.10.2026 20:00:00 EEST | Press release
Grafana Labs, the company behind the open agentic observability cloud, today announced new releases at ObservabilityCON 2026 that move Grafana Cloud towards agentic operations, including the general availability of Agent Observability with OpenTelemetry support and of Assistant Watchers, and previews of Grafana Pages and Grafana Managed Sandboxes. As AI moves into production, teams face two connected challenges: using agents to operate their systems and understanding the behavior of the agents themselves. In the 2026 State of Observability Report, also released this week by Grafana Labs and ETR, a Futurum company, 68% of the 300 IT and engineering leaders surveyed have moved AI for observability past investigation into pilots or production. But confidence depends on the task and readiness varies: 85% report comfort with read-only investigation, compared to 52% for full autonomous remediation. Grafana Labs is building toward a platform with agents that act, allowing each organization to
Nissan Technical Centre Europe Adopts Sonatus Fastlane™ Platform to Accelerate Vehicle Test and Validation20.10.2026 19:37:00 EEST | Press release
Following a successful proof of concept and ongoing engineering development over the past 12 months, Nissan Technical Centre Europe (NTCE), Nissan’s primary R&D hub for its global regions, is expanding its use of the Sonatus® Fastlane™ Platform across its pre-start-of-production (SOP) validation workflow. The platform’s event-driven data collection and root-cause analysis have reduced the time NTCE engineers spend investigating vehicle software issues from two weeks to two days. NTCE plans to make the platform a standard part of validating future vehicle programs, including upcoming models such as the Nissan JUKE. With the Fastlane Platform, engineers have the data they need from the moment a fault occurs. Teams deploy targeted data-collection policies from the cloud, and capture begins automatically when a defined event is detected. Fastlane Insight then correlates that data with NTCE’s specifications, CAN maps, diagnostic databases, and issue history to point engineers to the most li
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom